

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 September 2018

Cumulative for August and September 2018



Contents

Summary of decisions effective 1 September 2018.....	3
Section H changes to Part II	5
Index.....	19

Summary of decisions

EFFECTIVE 1 SEPTEMBER 2018

- Adalimumab inj 20 mg per 0.4 ml syringe and 40 mg per 0.8 ml syringe (Humira) and inj 40 mg per 0.8 ml pen (HumiraPen) – amended restriction criteria
- Calamine (healthE Calamine Aqueous Cream BP) crm, aqueous, BP – new listing and addition of HSS
- Calcitonin (Miacalcic) inj 100 iu per ml 1 ml ampoule – listing new Pharmacode and delisting existing Pharmacode
- Compound electrolytes with glucose [dextrose] (Pedialyte – Bubblegum) soln with electrolytes (2 x 500 ml) – new listing, amended chemical name and presentation description
- Enteral feed 1.5kcal/ml (e.g Isosource Standard RTH) Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle – delisted 1 September 2018
- Eptifibatide (Integrilin) inj 2 mg per ml, 10 ml vial and inj 750 mcg per ml, 100 ml vial – price increase and addition of HSS
- Ethosuximide (Zarontin) cap 250 mg and oral liq 50 mg per ml – new listing
- Fentanyl (Boucher and Muir) inj 50 mcg per ml, 2 ml and 10 ml ampoule – price decrease and addition of HSS
- Fluorouracil (Fluorouracil Ebewe) inj 5- mg per ml, 50 ml vial – to be delisted 1 March 2019
- Fluticasone propionate (Flixonase Hayfever & Allergy) nasal spray 50 mcg per dose, 120 dose – price decrease and addition of HSS
- Gentamicin sulphate (APP Pharmaceuticals) inj 10 mg per ml, 2 ml ampoule – to be delisted 1 April 2019
- Heparin sodium (Pfizer) inj 1,000 iu per ml and 5,000 iu per ml, 5 ml ampoule – price decrease and addition of HSS
- Isoprenaline [isoproterenol] inj 200 mcg per ml, 1 ml and 5 ml ampoule – amended chemical name
- Letrozole (Letrole) tab 2.5 mg – price increase and addition of HSS
- Lidocaine [lignocaine] hydrochloride (Orion) gel 2%, 20 g – price increase, addition of HSS and amended unit of measure
- Magnesium chloride inj 1 mmol per 1 ml, 100 ml bag – new listing
- Mometasone furoate crm 0.1%, 15 g (Elocon Alcohol Free) and oint 0.1%, 15 g and 50 g (Elocon) – addition of HSS
- Mometasone furoate crm 0.1%, 50 g (Elocon Alcohol Free) and lotn 0.1%, 30 ml (Elocon) – price decrease and addition of HSS

Summary of decisions – effective 1 September 2018 (continued)

- Moxifloxacin tab 400 mg (Avelox) and inj 1.6 mg per ml, 250 ml bottle (Avelox IV 400) – amended restriction criteria
- Oxytocin (Oxytocin BNM) inj 5 iu per ml and 10 iu per ml, 1 ml ampoule – price decrease and addition of HSS
- Paracetamol (Gacet) suppos 125 mg – price decrease and addition of HSS
- Paracetamol (Gacet) suppos 250 mg – addition of HSS
- Promethazine theoclate tab 25 mg – to be delisted 1 December 2018
- Quinapril tab 5 mg (Arrow-Quinapril 5) and tab 10 mg (Arrow-Quinapril 10) – price increase and addition of HSS
- Quinapril (Arrow-Quinapril 20) tab 20 mg – price decrease and addition of HSS
- Ritonavir oral liq 80 mg per ml – delisted 1 September 2018
- Rivaroxaban (Xarelto) tab 10 mg; 15 tab pack – to be delisted 1 December 2018
- Salbutamol (Ventolin) oral liq 400 mcg per ml – price increase and addition of HSS
- Sildenafil (Vedafil) tab 25 mg, 50 mg, 100 mg and inj 0.8 mg per ml, 12.5 ml vial – amended restriction criteria
- Temozolomide (Orion Temozolomide) cap 5 mg, 20 mg, 100 mg and 250 mg – amended restriction criteria
- Testosterone undecanoate (Andriol Testocaps) cap 40 mg – price increase and addition of HSS
- Thiamine hydrochloride (Max Health) tab 50 mg – new listing and addition of HSS
- Verapamil hydrochloride (Isoptin) inj 2.5 mg per ml, 2 ml ampoule – listing new Pharmacode and delisting existing Pharmacode

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 September 2018

ALIMENTARY TRACT AND METABOLISM

17	MAGNESIUM CHLORIDE (new listing) Inj 1 mmol per 1 ml, 100 ml bag			
20	THIAMINE HYDROCHLORIDE (new listing) Tab 50 mg – 1% DV Nov-18 to 2020	4.89	100	Max Health

BLOOD AND BLOOD FORMING ORGANS

28	HEPARIN SODIUM (↓ price and addition of HSS) Inj 1,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021	58.57	50	Pfizer
	Inj 5,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021	203.68	50	Pfizer
28	RIVAROXABAN (delisting) Tab 10 mg	41.55	15	Xarelto
	Note – Xarelto tab 10 mg, 15 tab pack to be delisted from 1 December 2018.			
29	EPTIFIBATIDE (↑ price and addition of HSS) → Inj 2 mg per ml, 10 ml vial – 1% DV Nov-18 to 2021	138.75	1	Integrilin
	→ Inj 750 mcg per ml, 100 ml vial – 1% DV Nov-18 to 2021	405.00	1	Integrilin
33	COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] (new listing, amended chemical name and presentation description) Soln with electrolytes (2 x 500 ml) – 1% DV Nov-18 to 2021	6.55	1,000 ml	Pedialyte – Bubblegum

CARDIOVASCULAR SYSTEM

35	QUINAPRIL (↑ price and addition of HSS) Tab 5 mg – 1% DV Nov-18 to 2021	6.01	90	Arrow-Quinapril 5
	Tab 10 mg – 1% DV Nov-18 to 2021	3.16	90	Arrow-Quinapril 10
35	QUINAPRIL (↓ price and addition of HSS) Tab 20 mg – 1% DV Nov-18 to 2021	4.89	90	Arrow-Quinapril 20
40	VERAPAMIL HYDROCHLORIDE (Pharmacode change) Inj 2.5 mg per ml, 2 ml ampoule	25.00	5	Isoptin
	Note – this is a new Pharmacode listing, 2535351. Pharmacode 253480 to be delisted from 1 March 2019.			
44	ISOPRENALINE [ISOPROTERENOL] (amended chemical name) Inj 200 mcg per ml, 1 ml ampoule Inj 200 mcg per ml, 5 ml ampoule			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2018 (continued)

46	SILDENAFIL (amended restriction – affected criteria shown only)			
	→ Tab 25 mg – 1% DV Sep-18 to 2021	0.64	4	Vedafil
	→ Tab 50 mg – 1% DV Sep-18 to 2021	0.64	4	Vedafil
	→ Tab 100 mg – 1% DV Sep-18 to 2021	6.60	12	Vedafil
	→ Inj 0.8 mg per ml, 12.5 ml vial			
	Restricted			
	Initiation – tablets Pulmonary arterial hypertension			
	Any of the following:			
	1 All of the following:			
	1.1 Patient has pulmonary arterial hypertension (PAH)*; and			
	1.2 Any of the following:			
	1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or			
	1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications, or			
	1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and			
	1.3 Any of the following:			
	1.3.1 PAH is in NYHA/WHO functional class II; or			
	1.3.2 PAH is in NYHA/WHO functional class III; or			
	1.3.3 PAH is in NYHA/WHO functional class IV; and			
	1.4 Either:			
	1.4.1 All of the following:			
	1.4.1.1 1-4 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and			
	1.4.1.2 1-5 Either:			
	1.4.1.2.1 1-5-1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or			
	1.4.1.2.2 1-5-2 Patient is peri Fontan repair; and			
	1.4.1.3 1-6 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm ⁻⁵); or			
	1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient's young age; or			
	2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or			
	3 In-hospital stabilisation in emergency situations			

DERMATOLOGICALS

50	CALAMINE (brand change)			
	Crm, aqueous, BP – 1% DV Nov-18 to 2021	1.26	100 g	healthE Calamine Aqueous Cream BP
	Note – Pharmacy Health crm, aqueous, BP to be delisted from 1 November 2018.			
52	MOMETASONE FUROATE (addition of HSS)			
	Crm 0.1% – 1% DV Nov-18 to 2021	1.51	15 g	Elocon Alcohol Free
	Oint 0.1% – 1% DV Nov-18 to 2021	1.51	15 g	Elocon
		2.90	50 g	Elocon
52	MOMETASONE FUROATE (↓ price and addition of HSS)			
	Crm 0.1% – 1% DV Nov-18 to 2021	2.50	50 g	Elocon Alcohol Free
	Lotn 0.1% – 1% DV Nov-18 to 2021	6.30	30 ml	Elocon

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2018 (continued)

GENITO-URINARY SYSTEM

57	OXYTOCIN (4 price and addition of HSS)			
	Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021	3.98	5	Oxytocin BNM
	Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021	4.98	5	Oxytocin BNM

HORMONE PREPARATIONS

60	CALCITONIN (Pharmacode change)			
	Inj 100 iu per ml, 1 ml ampoule	121.00	5	Miacalcic
	Note – this is a new Pharmacode listing, 2548356. Pharmacode 259012 to be delisted from 1 March 2019.			
60	TESTOSTERONE UNDECANOATE (↑ price and addition of HSS)			
	Cap 40 mg – 1% DV Nov-18 to 2021	21.00	60	Andriol Testocaps

INFECTIONS

70	GENTAMICIN SULPHATE (delisting)			
	Inj 10 mg per ml, 2 ml ampoule	175.10	25	APP Pharmaceuticals
	Note – APP Pharmaceutical inj 10 mg per ml, 2 ml ampoule to be delisted from 1 April 2019.			
75	MOXIFLOXACIN (amended restriction – affected criteria shown only)			
	→ Tab 400 mg	52.00	5	Avelox
	→ Inj 1.6 mg per ml, 250 ml bottle	70.00	1	Avelox IV 400

Restricted

Initiation – Mycobacterium infection

Infectious disease specialist, clinical microbiologist or respiratory specialist

Any of the following Either:

1 Both:

1.1 Active tuberculosis; and

1.2 Any of the following:

1.2.1 Documented resistance to one or more first-line medications; or

1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or

1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or

1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or

1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or

3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

Initiation – Mycoplasma genitalium

All of the following:

1 Has nucleic acid amplification test (NAAT) confirmed *Mycoplasma genitalium* **and is symptomatic**; and

2 Either:

2.1 Has tried and failed to clear infection using azithromycin; ~~and~~ or

2.2 Has laboratory confirmed azithromycin resistance; and

3 Treatment is only for 7 days.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2018 (continued)

- 85 RITONAVIR (delisting)
 → Oral liq 80 mg per ml
 Note – Ritonavir oral liq 80 mg per ml to be delisted from 1 September 2018.

NERVOUS SYSTEM

- 106 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ price, addition of HSS and amended unit of measure)
 Gel 2% – **1% DV Nov-18 to 2021** 4.87 20 g **Orion**
- 107 PARACETAMOL (addition of HSS)
 Suppos 125 mg – **1% DV Nov-18 to 2021** (↓ price)..... 3.29 10 **Gacet**
 Suppos 250 mg – **1% DV Nov-18 to 2021**..... 3.79 10 **Gacet**
- 108 FENTANYL (↓ price and addition of HSS)
 Inj 50 mcg per ml, 2 ml ampoule – **1% DV Nov-18 to 2021** 3.56 10 **Boucher and Muir**
 Inj 50 mcg per ml, 10 ml ampoule – **1% DV Nov-18 to 2021** 9.41 10 **Boucher and Muir**
- 112 ETHOSUXIMIDE (new listing)
 Cap 250 mg 281.75 200 Zarontin
 Oral liq 50 mg per ml 56.35 200 ml Zarontin
- 117 PROMETHAZINE THEOCLATE (delisting)
 → Tab 25 mg
 Note – Promethazine theoclate tab 25 mg to be delisted from 1 December 2018.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

- 131 FLUOROURACIL (delisting)
 Inj 50 mg per ml, 50 ml vial 17.00 1 Fluorouracil Ebewe
 Note – Fluorouracil Ebewe inj 50 mg per ml, 50 ml vial to be delisted from 1 March 2019.
- 135 TEMOZOLOMIDE (amended restriction – affected criteria shown only)
 → Cap 5 mg – **1% DV Feb-17 to 2019** 10.20 5 **Orion Temozolomide**
 → Cap 20 mg – **1% DV Feb-17 to 2019** 18.30 5 **Orion Temozolomide**
 → Cap 100 mg – **1% DV Feb-17 to 2019** 40.20 5 **Orion Temozolomide**
 → Cap 250 mg – **1% DV Feb-17 to 2019** 96.80 5 **Orion Temozolomide**

Restricted

Initiation – Ewing’s Sarcoma
Reassessment required after 9 months
Patient has relapse or refractory Ewing’s sarcoma.

Continuation – Ewing’s Sarcoma
Reassessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

→ Restriction
 (Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 September 2018 (continued)

144	LETROZOLE (↑ price and addition of HSS) Tab 2.5 mg – 1% DV Nov-18 to 2021	4.68	30	Letrole
151	ADALIMUMAB (amended restrictions – affected criteria shown only) → Inj 20 mg per 0.4 ml syringe	1,599.96	2	Humira
	→ Inj 40 mg per 0.8 ml pen.....	1,599.96	2	HumiraPen
	→ Inj 40 mg per 0.8 ml syringe	1,599.96	2	Humira

Restricted

Initiation – Crohn's disease – **adults**

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn's disease – **adults**

Gastroenterologist

Re-assessment required after 3 months

Both:

- 1 Either:
 - 1.1 Either:
 - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.1.2 CDAI score is 150 or less; or
 - 1.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Crohn's disease – **children**

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2018 (continued)

continued...

Continuation – Crohn's disease – children

Gastroenterologist

Re-assessment required after 3 months

Both:

1 Any of the following:

- 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 1.2 PCDAI score is 15 or less; or
- 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

RESPIRATORY SYSTEM AND ALLERGIES

186	FLUTICASONE PROPIONATE (↓ price and addition of HSS) Nasal spray 50 mcg per dose – 1% DV Nov-18 to 2021	1.98	120 dose	Flixonase Hayfever & Allergy
188	SALBUTAMOL (↑ price and addition of HSS) Oral liq 400 mcg per ml – 1% DV Nov-18 to 2021	20.00	150 ml	Ventolin

SPECIAL FOODS

223	ENTERAL FEED 1.5 KCAL/ML (delisting) → Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle			<i>e.g. Isosource Standard RTH</i>
-----	--	--	--	--

Note – Enteral feed 1.5 kcal/ml (e.g. Isosource Standard RTH) liquid, 1,000 ml bottle to be delisted 1 September 2018.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018

ALIMENTARY TRACT AND METABOLISM

5	ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE SIMETHICONE (amended chemical name and presentation description) Tab 200 mg with magnesium hydroxide 200 mg and simeticone simethicone 20 mg Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone simethicone 30 mg per 5 ml			<i>e.g. Mylanta</i> <i>e.g. Mylanta Double Strength</i>
5	SIMETICONE SIMETHICONE (amended chemical name) Oral drops 100 mg per ml			
5	SIMETICONE (new listing) Oral drops 20 mg per 0.3 ml			
10	GLIBENCLAMIDE (new listing) Tab 5 mg – 1% DV Oct-18 to 2021	6.00	100	Daonil
10	PIOGLITAZONE (addition of HSS) Tab 15 mg – 1% DV Oct-18 to 2021	3.47	90	Vexazone
	Tab 30 mg – 1% DV Oct-18 to 2021	5.06	90	Vexazone
	Tab 45 mg – 1% DV Oct-18 to 2021	7.10	90	Vexazone
12	GLYCEROL (↑ price and addition of HSS) Suppos 3.6 g – 1% DV Oct-18 to 2021	9.25	20	PSM
15	IMIGLUCERASE (delisting) → Inj 40 iu per ml, 5 ml vial → Inj 40 iu per ml, 10 ml vial Note – Imiglucerase inj 40 iu per ml, 5 ml and 10 ml vials to be delisted from 1 March 2019.			
16	TALIGLUCERASE ALFA (new listing) → Inj 200 unit vial	1,072.00	1	Elelyso
	Restricted Initiation Only for use in patients with approval by the Gaucher's Treatment Panel.			
17	FERROUS SULPHATE (Pharmacode change) Tab long-acting 325 mg (105 mg elemental) – 1% DV Jun-18 to 2021	2.06	30	Ferrograd
	Note – this is a new Pharmacode listing, 2534819. 604321 to be delisted from 1 February 2019.			

BLOOD AND BLOOD FORMING ORGANS

23	FOLIC ACID (↑ price and addition of HSS) Tab 0.8 mg – 1% DV Oct-18 to 2021	21.84	1,000	Apo-Folic Acid
	Tab 5 mg – 1% DV Oct-18 to 2021	12.12	500	Apo-Folic Acid

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2018 (continued)				
25	TRANEXAMIC ACID (pack size correction) Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021 ...	10.95	5 40	Tranexamic-AFT
	Note – this is a correction to the pack size only.			
28	RIVAROXABAN (↓ price and restriction removed) → Tab 10 mg	41.55	15	Xarelto
	Restricted Initiation – total hip replacement <i>Limited to 5 weeks treatment</i> For the prophylaxis of venous thromboembolism. Initiation – total knee replacement <i>Limited to 2 weeks treatment</i> For the prophylaxis of venous thromboembolism.			
28	RIVAROXABAN (new listing) Tab 10 mg	83.10	30	Xarelto
	Tab 15 mg	77.56	28	Xarelto
	Tab 20 mg	77.56	28	Xarelto
33	SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE] (↑ price and addition of HSS) Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-18 to 2021	48.70	5	Biomed
33	POTASSIUM CHLORIDE (↑ price and addition of HSS) Tab long-acting 600 mg (8 mmol) – 1% DV Oct-18 to 2021	8.90	200	Span-K

CARDIOVASCULAR SYSTEM

35	TRANDOLAPRIL (delisting) → Cap 1 mg → Cap 2 mg Note – Trandolapril cap 1 mg and 2 mg to be delisted from 1 January 2019.			
35	ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE (delisting) → Tab 20 mg with hydrochlorothiazide 12.5 mg Note – Enalapril maleate with hydrochlorothiazide tab 20 mg with hydrochlorothiazide 12.5 mg to be delisted from 1 January 2019.			
37	ATROPINE SULPHATE (brand change) Inj 600 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021	12.07	10	Martindale
	Note – AstraZeneca inj 600 mcg per ml, 1 ml ampoule to be delisted from 1 October 2018.			
38	METOPROLOL TARTRATE (brand change) Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022	29.50	5	Metoprolol IV Mylan
	Note – Lopresor inj 1 mg per ml, 5 ml vial to be delisted from 1 February 2019.			
38	METOPROLOL TARTRATE (↑ price and addition of HSS) Tab 50 mg – 1% DV Oct-18 to 2021	5.66	100	Apo-Metoprolol
	Tab 100 mg – 1% DV Oct-18 to 2021	7.55	60	Apo-Metoprolol

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2018 (continued)				
38	NADOLOL (↑ price and addition of HSS)			
	Tab 40 mg – 1% DV Oct-18 to 2021	16.69	100	Apo-Nadolol
	Tab 80 mg – 1% DV Oct-18 to 2021	26.43	100	Apo-Nadolol
38	PINDOLOL (↑ price and addition of HSS)			
	Tab 5 mg – 1% DV Oct-18 to 2021	13.22	100	Apo-Pindolol
	Tab 10 mg – 1% DV Oct-18 to 2021	23.12	100	Apo-Pindolol
	Tab 15 mg – 1% DV Oct-18 to 2021	33.31	100	Apo-Pindolol
38	PROPRANOLOL (↑ price and addition of HSS)			
	Tab 10 mg – 1% DV Oct-18 to 2021	4.64	100	Apo-Propranolol
	Tab 40 mg – 1% DV Oct-18 to 2021	5.72	100	Apo-Propranolol
39	ISRADIPINE (delisting)			
	Cap long-acting 2.5 mg			
	Cap long-acting 5 mg			
	Note – Isradipine cap long-acting 2.5 mg and 5 mg to be delisted from 1 October 2018.			
39	DILTIAZEM HYDROCHLORIDE (↑ price and addition of HSS)			
	Cap long-acting 120 mg – 1% DV Oct-18 to 2021	33.42	500	Apo-Diltiazem CD
	Cap long-acting 180 mg – 1% DV Oct-18 to 2021	50.05	500	Apo-Diltiazem CD
	Cap long-acting 240 mg – 1% DV Oct-18 to 2021	66.76	500	Apo-Diltiazem CD
39	NIFEDIPINE (HSS suspended)			
	Tab long-acting 30 mg – 1% DV Dec-17 to 31 Jul 18 2020.....	3.14	30	Adalat Oros
40	VERAPAMIL HYDROCHLORIDE (Pharmacode change)			
	Tab 80 mg	11.74	100	Isoptin
	Note – this is a listing of a new Pharmacode, 2535335. Pharmacode 253502 to be delisted from 1 July 2019.			
40	CLONIDINE HYDROCHLORIDE (↓ price and addition of HSS)			
	Tab 25 mcg – 1% DV Oct-18 to 2021	8.75	112	Clonidine BNM
40	CLONIDINE HYDROCHLORIDE (brand change)			
	Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021	25.96	10	Medsurge
	Note – Catapres inj 150 mcg per ml, 1 ml ampoule to be delisted from 1 October 2018.			
43	DOBUTAMINE HYDROCHLORIDE (brand change)			
	Inj 12.5 mg per ml, 20 ml ampoule	61.13	5	Dobutamine-hameln
	Note – Dobutamine-hameln inj 12.5 mg per ml, 20 ml ampoule to be delisted from 1 January 2019.			
45	BOSENTAN (brand change)			
	→ Tab 62.5 mg – 1% DV Dec-18 to 2021	141.00	60	Bosentan Dr Reddy's
	→ Tab 125 mg – 1% DV Dec-18 to 2021	141.00	60	Bosentan Dr Reddy's
	Note – Bosentan-Mylan tab 62.5 mg and 125 mg to be delisted from 1 December 2018.			

DERMATOLOGICALS

50	ISOTRETINOIN (new listing)			
	Cap 5 mg – 1% DV Oct-18 to 2021	8.14	60	Oratane

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

50	ISOTRETINOIN (↓ price and addition of HSS)			
	Cap 10 mg – 1% DV Oct-18 to 2021	13.34	120	Oratane
	Cap 20 mg – 1% DV Oct-18 to 2021	20.49	120	Oratane
50	ISOTRETINOIN (delisting)			
	Cap 10 mg	12.47	100	Isotane 10
	Cap 20 mg	19.27	100	Isotane 20
	Note – Isotane 10 cap 10 mg and Isotane 20 cap 20 mg to be delisted from 1 October 2018.			
51	AQUEOUS CREAM (↑ price and addition of HSS)			
	Crm 100 g – 1% DV Oct-18 to 2021	1.05	100 g	Pharmacy Health SLS-free
	Note: DV limit applies to the pack sizes of 100 g or less.			
52	BETAMETHASONE VALERATE (↑ price and addition of HSS)			
	Crm 0.1% – 1% DV Oct-18 to 2021	3.45	50 g	Beta Cream
	Oint 0.1% – 1% DV Oct-18 to 2021	3.45	50 g	Beta Ointment
53	BETAMETHASONE VALERATE (addition of HSS)			
	Scalp app 0.1% – 1% DV Oct-18 to 2021	7.75	100 ml	Beta Scalp

GENITO-URINARY SYSTEM

57	OXYTOCIN WITH ERGOMETRINE MALEATE (↑ price and addition of HSS)			
	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021	15.00	5	Syntometrine
58	POTASSIUM CITRATE (↑ price and addition of HSS)			
	→ Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021	31.80	200 ml	Biomed

HORMONE PREPARATIONS

61	DEXAMETHASONE (↑ price and addition of HSS)			
	Tab 0.5 mg – 1% DV Oct-18 to 2021	0.99	30	Dexamethsone
	Tab 4 mg – 1% DV Oct-18 to 2021	1.90	30	Dexamethsone
64	SOMATROPIN (↓ price and addition of HSS)			
	→ Inj 5 mg cartridge – 1% DV Oct-18 to 2021	34.88	1	Omnitrope
	→ Inj 10 mg cartridge – 1% DV Oct-18 to 2021	69.75	1	Omnitrope
	→ Inj 15 mg cartridge – 1% DV Oct-18 to 2021	104.63	1	Omnitrope

INFECTIONS

71	MEROPENEM (brand change)			
	→ Inj 500 mg vial – 1% DV Oct-18 to 2020	4.00	1	Meropenem Ranbaxy
	→ Inj 1 g vial – 1% DV Oct-18 to 2020	8.00	1	Meropenem Ranbaxy
	Note – DBL Meropenem inj 500 mg and 1 g vial to be delisted from 1 October 2018.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2018 (continued)			
71	CEFALEXIN (↑ price and addition of HSS)		
	Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021	8.75	100 ml
	Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021	11.75	100 ml
74	FLUCLOXACILLIN (addition of HSS)		
	Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021	2.29	100 ml
	Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021 (↑ price)	3.68	100 ml
75	CIPROFLOXACIN (↑ price and addition of HSS)		
	→ Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021	68.20	10
77	LINEZOLID (↓ price and addition of HSS)		
	→ Tab 600 mg – 1% DV Oct-18 to 2021	553.77	10
77	TRIMETHOPRIM (↑ price and addition of HSS)		
	Tab 300 mg – 1% DV Oct-18 to 2021	16.50	50
80	ISONIAZID (↑ price and addition of HSS)		
	→ Tab 100 mg – 1% DV Oct-18 to 2021	22.00	100
86	ENTECAVIR (new listing)		
	Tab 0.5 mg – 1% DV Nov-18 to 2021	52.00	30
	Note – Baraclude tab 0.5 mg to be delisted from 1 November 2018.		Entecavir Sandoz

MUSCULOSKELETAL SYSTEM

94	ETIDRONATE DISODIUM (delisting)		
	Tab 200 mg	13.50	100
	Note – Arrow-Etidronate tab 200 mg to be delisted from 1 January 2019.		Arrow-Etidronate
100	BACLOFEN (↑ price and addition of HSS)		
	Tab 10 mg – 1% DV Oct-18 to 2021	4.20	100
101	DICLOFENAC SODIUM (↑ price and addition of HSS)		
	Tab EC 50 mg – 1% DV Oct-18 to 2021	1.23	50
	Tab long-acting 75 mg – 1% DV Oct-18 to 2021	22.80	500
101	DICLOFENAC SODIUM (↓ price and addition of HSS)		
	Tab EC 25 mg – 1% DV Oct-18 to 2021	1.23	50
	Tab long-acting 100 mg – 1% DV Oct-18 to 2021	25.15	500
102	MELOXICAM (delisting)		
	→ Tab 7.5 mg		
	Note – Meloxicam tab 7.5 mg to be delisted from 1 November 2018		
102	NAPROXEN (↑ price and addition of HSS)		
	Tab long-acting 750 mg – 1% DV Oct-18 to 2021	6.16	28
	Tab long-acting 1 g – 1% DV Oct-18 to 2021	8.21	28
			Naprosyn SR 750 Naprosyn SR 1000

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

NERVOUS SYSTEM

108	FENTANYL (pack size change) Inj 20 mcg per ml, 50 ml syringe – 1% DV Oct-18 to 2021	18.74	1	Biomed
Note – Biomed inj 20 mcg per ml, 50 ml syringe, 10 pack to be delisted 1 October 2018.				
108	METHADONE HYDROCHLORIDE (↑ price and addition of HSS) Oral liq 2 mg per ml – 1% DV Oct-18 to 2021	5.79	200 ml	Biodone
	Oral liq 5 mg per ml – 1% DV Oct-18 to 2021	5.79	200 ml	Biodone Forte
	Oral liq 10 mg per ml – 1% DV Oct-18 to 2021	6.79	200 ml	Biodone Extra Forte
110	CLOMIPRAMINE HYDROCHLORIDE (↑ price and addition of HSS) Tab 10 mg – 1% DV Oct-18 to 2021	13.99	100	Apo-Clomipramine
	Tab 25 mg – 1% DV Oct-18 to 2021	9.46	100	Apo-Clomipramine
111	MIRTAZAPINE (↑ price and addition of HSS) Tab 30 mg – 1% DV Oct-18 to 2021	2.63	30	Apo-Mirtazapine
	Tab 45 mg – 1% DV Oct-18 to 2021	3.48	30	Apo-Mirtazapine
112	GABAPENTIN (restriction removed and brands delisted) Note: Gabapentin not to be given in combination with pregabalin Capsule 100 mg	7.16	100	Arrow-Gabapentin Neurontin Nupentin
	Capsule 300 mg	11.00	100	Arrow-Gabapentin Neurontin Nupentin
	Capsule 400 mg	13.75	100	Arrow-Gabapentin Neurontin Nupentin

Restricted

Initiation – preoperative and/or postoperative use
Limited to 8 days treatment

Initiation – pain management of burns patients
Re-assessment required after 1 month

Continuation – pain management of burns patients
Re-assessment required after 1 month

The treatment remains appropriate and the patient is benefiting from treatment.

Initiation – epilepsy

Re-assessment required after 15 months

Either:

1 – Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

2 – Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Continuation – epilepsy

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

continued...

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

continued...

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective

Initiation – Neuropathic pain or Chronic Kidney Disease-associated pruritus

Re-assessment required after 3 months

Either:

1 The patient has been diagnosed with neuropathic pain; or

2 Both:

2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and

2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

Continuation – Neuropathic pain or Chronic Kidney Disease-associated pruritus

Either:

1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or

2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: Indications marked with * are unapproved indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.

Note – Arrow-Gabapentin, Narontin and Nupentin brands of gabapentin cap 100 mg, 300 mg and 400 mg to be delisted 1 August 2018.

114	PHENOBARBITONE (↑ price and addition of HSS)			
	Tab 15 mg – 1% DV Oct-18 to 2021	40.00	500	PSM
	Tab 30 mg – 1% DV Oct-18 to 2021	40.00	500	PSM
120	ZIPRASIDONE (HSS delayed)			
	Cap 20 mg – 1% DV Sep-18 to 2021	14.50	60	Zusdone
120	OLANZAPINE (↓ price and addition of HSS)			
	→ Inj 210 mg vial – 1% DV Oct-18 to 2021	252.00	1	Zyprexa Relprev
	→ Inj 300 mg vial – 1% DV Oct-18 to 2021	414.00	1	Zyprexa Relprev
	→ Inj 405 mg vial – 1% DV Oct-18 to 2021	504.00	1	Zyprexa Relprev
124	DEXAMFETAMINE SULFATE (↑ price and addition of HSS)			
	→ Tab 5 mg – 1% DV Oct-18 to 2021	20.00	100	PSM

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

130	CYCLOPHOSPHAMIDE (↑ price and addition of HSS)			
	Inj 1 g vial – 1% DV Oct-18 to 2021	35.65	1	Endoxan
	Inj 2 g vial – 1% DV Oct-18 to 2021	71.25	1	Endoxan
131	FLUOROURACIL (addition of HSS)			
	Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021 (↑ price)	12.00	1	Fluorouracil Ebewe
	Inj 50 mg per ml, 100 ml vial – 1% DV Oct-18 to 2021	30.00	1	Fluorouracil Ebewe
143	MEGESTROL ACETATE (↑ price and addition of HSS)			
	Tab 160 mg – 1% DV Oct-18 to 2021	63.53	30	Apo-Megestrol

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

186	BUDESONIDE (brand change) Nasal spray 50 mcg per dose – 1% DV Oct-18 to 2020	2.59	200 dose	SteroClear
	Nasal spray 100 mcg per dose – 1% DV Oct-18 to 2020	2.87	200 dose	SteroClear
	Note – Butacort Aqueous nasal spray 50 mcg and 100 mcg per dose to be delisted from 1 October 2018.			
186	SALBUTAMOL WITH IPRATROPIUM BROMIDE († price and addition of HSS) Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Oct-18 to 2021	5.20	20	Duolin
188	SALBUTAMOL († price and addition of HSS) Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021	3.93	20	Asthalin
	Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021	4.03	20	Asthalin
191	BERACTANT (delisting) Soln 200 mg per 8 ml vial	550.00	1	Survanta
	Note – Survanta soln 200 mg per 8 ml vial to be delisted from 1 January 2019.			

SENSORY ORGANS

192	SODIUM FUSIDATE [FUSIDIC ACID] († price) Eye drops 1%	5.29	5 g	Fucithalmic
-----	--	------	-----	-------------

Index

Pharmaceuticals and brands

A			
Adalat Oros	13	Clonidine hydrochloride	13
Adalimumab	9	Compound electrolytes with glucose [dextrose]	5
Aluminium hydroxide with magnesium hydroxide and simethicone	11	Cyclophosphamide	17
Aluminium hydroxide with magnesium hydroxide and simeticone	11	D	
Andriol Testocaps	7	Daonil	11
Apo-Clomipramine	16	Dexamethasone	14
Apo-Diclo SR	15	Dexamfetamine sulfate	17
Apo-Diltiazem CD	13	Dexmethsone	14
Apo-Folic Acid	11	Dextrose	5
Apo-Megestrol	17	Diclofenac Sandoz	15
Apo-Metoprolol	12	Diclofenac sodium	15
Apo-Mirtazapine	16	Diltiazem hydrochloride	13
Apo-Nadolol	13	Dobutamine-hameln	13
Apo-Pindolol	13	Dobutamine hydrochloride	13
Apo-Propranolol	13	Duolin	18
Aqueous cream	14	E	
Arrow-Etidronate	15	Elelyso	11
Arrow-Gabapentin	16	Elocon	6
Arrow-Quinapril 5	5	Elocon Alcohol Free	6
Arrow-Quinapril 10	5	Enalapril maleate with hydrochlorothiazide	12
Arrow-Quinapril 20	5	Endoxan	17
Asthalin	18	Entecavir	15
Atropine sulphate	12	Entecavir Sandoz	15
Avelox	7	Enteral feed 1.5 kcal/ml	10
Avelox IV 400	7	Eptifibatide	5
B		Ethosuximide	8
Baclofen	15	Etidronate disodium	15
Beractant	18	F	
Beta Cream	14	Fentanyl	8, 16
Betamethasone valerate	14	Ferrograd	11
Beta Ointment	14	Ferrous sulphate	11
Beta Scalp	14	Flixonase Hayfever & Allergy	10
Biodone	16	Flucloxacillin	15
Biodone Extra Forte	16	Fluorouracil	8, 17
Biodone Forte	16	Fluorouracil Ebewe	8, 17
Bosentan	13	Fluticasone propionate	10
Bosentan Dr Reddy's	13	Folic acid	11
Budesonide	18	Fucithalmic	18
C		Fusidic acid	18
Calamine	6	G	
Calcitonin	8	Gabapentin	16
Cefalexin	15	Gacet	8
Cefalexin Sandoz	15	Gentamicin sulphate	7
Cipflox	15	Glibenclamide	11
Ciprofloxacin	15	Glycerol	11
Clomipramine hydrochloride	16	H	
Clonidine BNM	13	healthE Calamine Aqueous Cream BP	6
		Heparin sodium	5
		Humira	9
		HumiraPen	9

Index

Pharmaceuticals and brands

I	
Imiglucerase	11
Integrilin.....	5
Isoniazid	15
Isoprenaline [isoproterenol]	5
Isoproterenol.....	5
Isoptin	5, 13
Isosource Standard RTH	10
Isotane 10.....	14
Isotane 20.....	14
Isotretinoin.....	13, 14
Isradipine	13
L	
Letrole	9
Letrozole.....	9
Lidocaine [lignocaine] hydrochloride	8
Lignocaine	8
Linezolid	15
M	
Magnesium chloride.....	5
Megestrol acetate.....	17
Meloxicam.....	15
Meropenem	14
Meropenem Ranbaxy	14
Methadone hydrochloride	16
Metoprolol IV Mylan	12
Metoprolol tartrate.....	12
Miacalcic	8
Mirtazapine	16
Mometasone furoate	6
Moxifloxacin.....	7
Mylanta.....	11
Mylanta Double Strength	11
N	
Nadolol	13
Naprosyn SR 750.....	15
Naprosyn SR 1000.....	15
Naproxen	15
Neurontin	16
Nifedipine.....	13
Nupentin	16
O	
Olanzapine	17
Omnitrope.....	14
Oratane	13, 14
Orion Temozolomide	8
Oxytocin	7
Oxytocin BNM.....	7
Oxytocin with ergometrine maleate	14
P	
Pacifen	15
Paracetamol.....	8
Pedialyte Bubblegum	5
Pharmacy Health SLS-free	14
Phenobarbitone.....	17
Pindolol	13
Pioglitazone	11
Potassium chloride	12
Potassium citrate	14
Promethazine theoclate	8
Propranolol	13
Q	
Quinapril	5
R	
Ritonavir	8
Rivaroxaban.....	5, 12
S	
Salbutamol.....	10, 18
Salbutamol with ipratropium bromide.....	18
Sildenafil.....	6
Simethicone.....	11
Simeticone.....	11
Sodium acid phosphate.....	12
Sodium dihydrogen phosphate [sodium acid phosphate].....	12
Sodium fusidate [fusidic acid]	18
Somatropin	14
Span-K	12
SteroClear.....	18
Survanta	18
Syntometrine.....	14
T	
Taliglucerase alfa	11
Temozolomide	8
Testosterone undecanoate.....	7
Thiamine hydrochloride.....	5
TMP.....	15
Trandolapril.....	12
Tranexamic acid.....	12
Tranexamic-AFT.....	12
Trimethoprim	15
V	
Vedafil	6
Ventolin	10
Verapamil hydrochloride.....	5, 13
Vexazone	11
X	
Xarelto	5, 12

Index

Pharmaceuticals and brands

Z		
Zarontin	8	Zusdone..... 17
Ziprasidone	17	Zyprexa Relprevv..... 17
		Zyvox..... 15



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.